Li-Fraumeni syndrome with simultaneous osteosarcoma and liver cancer: Increased expression of a CD44 variant isoform after chemotherapy

Go J. Yoshida, Yasushi Fuchimoto, Tomoo Osumi, Hiroyuki Shimada, Seiichi Hosaka, Hideo Morioka, Makio Mukai, Yohei Masugi, Michiie Sakamoto, Tatsuo Kuroda

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Background: Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome that is commonly associated with a germline mutation in the tumor suppressor gene p53. Loss of p53 results in increased expression of CD44, a cancer stem cell (CSC) marker, which is involved in the scavenging of reactive oxygen species (ROS). Here, we report a change in the expression of a CD44 variant isoform (CD44v8-10) in an 8-year-old female LFS patient with osteosarcoma and atypical liver cancer after chemotherapy.Case presentation: The patient visited a clinic with a chief complaint of chronic pain in a bruise on her right knee. Magnetic resonance imaging (MRI) raised the possibility of a bone malignancy. Biochemical testing also revealed significantly elevated levels of AFP, which strongly suggested the existence of a primary malignancy in the liver. MRI imaging showed the simultaneous development of osteosarcoma and liver cancer, both of which were confirmed upon biopsy. Combined therapy with surgical resection after chemotherapy was successful in this patient. Regardless of the absence of a familial history of hereditary cancer, a germline mutation in p53 was identified (a missense mutation defined as c.722 C>T, p.Ser241Phe). To better understand the cancer progression and response to treatment, immunohistochemical (IHC) analysis of biopsy specimens obtained before and after chemotherapy was performed using a specific antibody against CD44v8-10.Conclusion: This case demonstrates the ectopic up-regulation of CD44v8-10 in a biopsy sample obtained after cytotoxic chemotherapy, which confers high levels of oxidative stress on cancer cells. Because the alternative splicing of CD44 is tightly regulated epigenetically, it is possible that micro-environmental stress resulting from chemotherapy caused the ectopic induction of CD44v8-10 in vivo.

Original languageEnglish
Article number444
JournalBMC Cancer
Volume12
DOIs
Publication statusPublished - 2012 Oct 2

Fingerprint

Li-Fraumeni Syndrome
Osteosarcoma
Liver Neoplasms
Protein Isoforms
Drug Therapy
Germ-Line Mutation
Neoplasms
Biopsy
Hereditary Neoplastic Syndromes
Magnetic Resonance Imaging
Neoplastic Stem Cells
Contusions
Alternative Splicing
Missense Mutation
Tumor Suppressor Genes
Chronic Pain
Reactive Oxygen Species
Knee
Oxidative Stress
Up-Regulation

Keywords

  • cancer stem cells (CSCs)
  • CD44 variant isoforms
  • Li-Fraumeni syndrome (LFS)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Li-Fraumeni syndrome with simultaneous osteosarcoma and liver cancer : Increased expression of a CD44 variant isoform after chemotherapy. / Yoshida, Go J.; Fuchimoto, Yasushi; Osumi, Tomoo; Shimada, Hiroyuki; Hosaka, Seiichi; Morioka, Hideo; Mukai, Makio; Masugi, Yohei; Sakamoto, Michiie; Kuroda, Tatsuo.

In: BMC Cancer, Vol. 12, 444, 02.10.2012.

Research output: Contribution to journalArticle

@article{f30de263015c4cd9b29e470c664908b9,
title = "Li-Fraumeni syndrome with simultaneous osteosarcoma and liver cancer: Increased expression of a CD44 variant isoform after chemotherapy",
abstract = "Background: Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome that is commonly associated with a germline mutation in the tumor suppressor gene p53. Loss of p53 results in increased expression of CD44, a cancer stem cell (CSC) marker, which is involved in the scavenging of reactive oxygen species (ROS). Here, we report a change in the expression of a CD44 variant isoform (CD44v8-10) in an 8-year-old female LFS patient with osteosarcoma and atypical liver cancer after chemotherapy.Case presentation: The patient visited a clinic with a chief complaint of chronic pain in a bruise on her right knee. Magnetic resonance imaging (MRI) raised the possibility of a bone malignancy. Biochemical testing also revealed significantly elevated levels of AFP, which strongly suggested the existence of a primary malignancy in the liver. MRI imaging showed the simultaneous development of osteosarcoma and liver cancer, both of which were confirmed upon biopsy. Combined therapy with surgical resection after chemotherapy was successful in this patient. Regardless of the absence of a familial history of hereditary cancer, a germline mutation in p53 was identified (a missense mutation defined as c.722 C>T, p.Ser241Phe). To better understand the cancer progression and response to treatment, immunohistochemical (IHC) analysis of biopsy specimens obtained before and after chemotherapy was performed using a specific antibody against CD44v8-10.Conclusion: This case demonstrates the ectopic up-regulation of CD44v8-10 in a biopsy sample obtained after cytotoxic chemotherapy, which confers high levels of oxidative stress on cancer cells. Because the alternative splicing of CD44 is tightly regulated epigenetically, it is possible that micro-environmental stress resulting from chemotherapy caused the ectopic induction of CD44v8-10 in vivo.",
keywords = "cancer stem cells (CSCs), CD44 variant isoforms, Li-Fraumeni syndrome (LFS)",
author = "Yoshida, {Go J.} and Yasushi Fuchimoto and Tomoo Osumi and Hiroyuki Shimada and Seiichi Hosaka and Hideo Morioka and Makio Mukai and Yohei Masugi and Michiie Sakamoto and Tatsuo Kuroda",
year = "2012",
month = "10",
day = "2",
doi = "10.1186/1471-2407-12-444",
language = "English",
volume = "12",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Li-Fraumeni syndrome with simultaneous osteosarcoma and liver cancer

T2 - Increased expression of a CD44 variant isoform after chemotherapy

AU - Yoshida, Go J.

AU - Fuchimoto, Yasushi

AU - Osumi, Tomoo

AU - Shimada, Hiroyuki

AU - Hosaka, Seiichi

AU - Morioka, Hideo

AU - Mukai, Makio

AU - Masugi, Yohei

AU - Sakamoto, Michiie

AU - Kuroda, Tatsuo

PY - 2012/10/2

Y1 - 2012/10/2

N2 - Background: Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome that is commonly associated with a germline mutation in the tumor suppressor gene p53. Loss of p53 results in increased expression of CD44, a cancer stem cell (CSC) marker, which is involved in the scavenging of reactive oxygen species (ROS). Here, we report a change in the expression of a CD44 variant isoform (CD44v8-10) in an 8-year-old female LFS patient with osteosarcoma and atypical liver cancer after chemotherapy.Case presentation: The patient visited a clinic with a chief complaint of chronic pain in a bruise on her right knee. Magnetic resonance imaging (MRI) raised the possibility of a bone malignancy. Biochemical testing also revealed significantly elevated levels of AFP, which strongly suggested the existence of a primary malignancy in the liver. MRI imaging showed the simultaneous development of osteosarcoma and liver cancer, both of which were confirmed upon biopsy. Combined therapy with surgical resection after chemotherapy was successful in this patient. Regardless of the absence of a familial history of hereditary cancer, a germline mutation in p53 was identified (a missense mutation defined as c.722 C>T, p.Ser241Phe). To better understand the cancer progression and response to treatment, immunohistochemical (IHC) analysis of biopsy specimens obtained before and after chemotherapy was performed using a specific antibody against CD44v8-10.Conclusion: This case demonstrates the ectopic up-regulation of CD44v8-10 in a biopsy sample obtained after cytotoxic chemotherapy, which confers high levels of oxidative stress on cancer cells. Because the alternative splicing of CD44 is tightly regulated epigenetically, it is possible that micro-environmental stress resulting from chemotherapy caused the ectopic induction of CD44v8-10 in vivo.

AB - Background: Li-Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome that is commonly associated with a germline mutation in the tumor suppressor gene p53. Loss of p53 results in increased expression of CD44, a cancer stem cell (CSC) marker, which is involved in the scavenging of reactive oxygen species (ROS). Here, we report a change in the expression of a CD44 variant isoform (CD44v8-10) in an 8-year-old female LFS patient with osteosarcoma and atypical liver cancer after chemotherapy.Case presentation: The patient visited a clinic with a chief complaint of chronic pain in a bruise on her right knee. Magnetic resonance imaging (MRI) raised the possibility of a bone malignancy. Biochemical testing also revealed significantly elevated levels of AFP, which strongly suggested the existence of a primary malignancy in the liver. MRI imaging showed the simultaneous development of osteosarcoma and liver cancer, both of which were confirmed upon biopsy. Combined therapy with surgical resection after chemotherapy was successful in this patient. Regardless of the absence of a familial history of hereditary cancer, a germline mutation in p53 was identified (a missense mutation defined as c.722 C>T, p.Ser241Phe). To better understand the cancer progression and response to treatment, immunohistochemical (IHC) analysis of biopsy specimens obtained before and after chemotherapy was performed using a specific antibody against CD44v8-10.Conclusion: This case demonstrates the ectopic up-regulation of CD44v8-10 in a biopsy sample obtained after cytotoxic chemotherapy, which confers high levels of oxidative stress on cancer cells. Because the alternative splicing of CD44 is tightly regulated epigenetically, it is possible that micro-environmental stress resulting from chemotherapy caused the ectopic induction of CD44v8-10 in vivo.

KW - cancer stem cells (CSCs)

KW - CD44 variant isoforms

KW - Li-Fraumeni syndrome (LFS)

UR - http://www.scopus.com/inward/record.url?scp=84866791348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866791348&partnerID=8YFLogxK

U2 - 10.1186/1471-2407-12-444

DO - 10.1186/1471-2407-12-444

M3 - Article

C2 - 23031740

AN - SCOPUS:84866791348

VL - 12

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 444

ER -